Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J receives subpoena for Natrecor marketing documents

Executive Summary

The Boston U.S. Attorney's office issues subpoena to Johnson & Johnson subsidiary Scios requesting documents related to the sales and marketing of its congestive heart failure drug Natrecor (nesiritide), the company announced July 20. The subpoena comes on the heels of a New England Journal of Medicine article by Eric Topol (Cleveland Clinic) asserting that Scios has conducted an "aggressive marketing campaign" to promote Natrecor for serial outpatient use (1"The Pink Sheet" July 18, 2005, p. 9)...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS046120

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel